1. Home
  2. JKS vs CGEM Comparison

JKS vs CGEM Comparison

Compare JKS & CGEM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo JinkoSolar Holding Company Limited (each representing 4)

JKS

JinkoSolar Holding Company Limited (each representing 4)

N/A

Current Price

$16.62

Market Cap

1.0B

Sector

Technology

ML Signal

N/A

Logo Cullinan Oncology Inc.

CGEM

Cullinan Oncology Inc.

N/A

Current Price

$20.59

Market Cap

1.1B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
JKS
CGEM
Founded
2006
2016
Country
China
United States
Employees
N/A
N/A
Industry
Semiconductors
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.0B
1.1B
IPO Year
2010
2020

Fundamental Metrics

Financial Performance
Metric
JKS
CGEM
Price
$16.62
$20.59
Analyst Decision
Hold
Strong Buy
Analyst Count
5
8
Target Price
$24.80
$30.13
AVG Volume (30 Days)
611.2K
576.3K
Earning Date
04-29-2026
05-11-2026
Dividend Yield
6.04%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$14.60
$5.20
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$14.55
$5.68
52 Week High
$31.88
$21.00

Technical Indicators

Market Signals
Indicator
JKS
CGEM
Relative Strength Index (RSI) 49.79 72.03
Support Level $14.94 $16.40
Resistance Level $17.27 N/A
Average True Range (ATR) 0.73 1.18
MACD 0.19 0.31
Stochastic Oscillator 67.42 96.18

Price Performance

Historical Comparison
JKS
CGEM

About JKS JinkoSolar Holding Company Limited (each representing 4)

JinkoSolar Holding Co Ltd is engaged in the photovoltaic industry. The firm has built a vertically integrated solar power product value chain, manufacturing from silicon wafers to solar modules. It sells solar modules under the JinkoSolar brand. The company's products include Silicon wafers, Solar cells, and Solar modules. Its geographical segments are China (including Hong Kong and Taiwan), the Americas, Europe, Asia Pacific, and the Rest of the world.

About CGEM Cullinan Oncology Inc.

Cullinan Therapeutics Inc is a clinical-stage biopharmaceutical company developing therapies for autoimmune diseases and cancer. Its development pipeline comprises the following drug candidates: CLN-978, a CD19xCD3 bispecific T cell engager that is being developed for autoimmune diseases; CLN-049, a FLT3xCD3 bispecific T cell engager being evaluated in an ongoing clinical trial in patients with relapsed/refractory acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS); Velinotamig, a BCMAxCD3 bispecific T cell engager being developed to counter autoimmune diseases; and Zipalertinib, being developed as a treatment for non-small cell lung cancer. Additionally, the company is developing several preclinical programs in autoimmune diseases and oncology.

Share on Social Networks: